FDA accepts resubmitted BLA from Outlook Therapeutics

▤ Summary

Outlook Therapeutics says the FDA accepted its resubmitted BLA for ONS-5010/Lytenava for age-related macular degeneration. The application received a Class 1 review, which puts the target action date at July 29, 2026. The market responded positively, with the company’s shares rising more than 25% on the news. This is a meaningful regulatory milestone for the company, but it is not a software product or corporate transaction.

▦ Linked Companies